Evexomostat - SynDevRx
Alternative Names: MetAP2 inhibitor - SynDevRx; SDX-7320Latest Information Update: 27 Jun 2023
At a glance
- Originator SynDevRx, Inc
- Developer Memorial Sloan-Kettering Cancer Center; SynDevRx, Inc
- Class Antineoplastics; Cyclohexanes; Drug conjugates; Sesquiterpenes; Unsaturated fatty acids
- Mechanism of Action DNA synthesis inhibitors; Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Triple negative breast cancer
- Phase I/II Breast cancer
- Phase I Solid tumours
- Preclinical Colorectal cancer; Interstitial lung diseases
Most Recent Events
- 27 Jun 2023 3798119- No significant data, only methods of trial mentioned
- 14 Apr 2023 Pharmacodynamics data from the preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 03 Oct 2022 Phase-II clinical trials in Triple-negative-breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT05570253)